Drug Search Results
More Filters [+]

Bemcentinib

Alternative Names: bemcentinib, bgb-324, bgb324, bgb 324
Latest Update: 2024-10-07
Latest Update Note: News Article

Product Description

Bemcentinib has been studied in 179 hospitalized patients with COVID-19 compared with standard-of-care therapies.Ê Preliminary data indicate that bemcentinib in addition to standard of care therapies provides added sustained protection against worsening of lung damage in patients who need of oxygen treatment, thus reducing the chances of needing a ventilator to help their breathing and aiding in their recovery. (Sourced from: https://www.bergenbio.com/pipeline/bemcentinib-covid-19/)

Mechanisms of Action: AXL Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Lung Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer
Fast Track - Non-Small-Cell Lung Cancer|Small Cell Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BerGenBio AS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bemcentinib

Countries in Clinic: France, Greece, Hungary, Italy, Norway, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Adenocarcinoma|Melanoma|Mesothelioma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Phase 1: Acute Myeloid Leukemia|COVID-19|Glioblastoma|Myelodysplastic Syndrome|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BGBC016

P2

Unknown Status

Non-Small-Cell Lung Cancer

2025-10-01

BGBC016

P2

Recruiting

Non-Small-Cell Lung Cancer

2025-08-11

57%

2019-003806-28

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2025-05-13

Combination study of BGB324 in melanoma

P2

Completed

Melanoma

2024-05-23

Recent News Events